Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419994 | PMC |
| http://dx.doi.org/10.1016/j.hrcr.2016.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolving use of quinidine in the treatment of ventricular arrhythmias.
Trends Cardiovasc Med
August 2024
Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, United States. Electronic address:
Quinidine for ventricular arrhythmias: A comprehensive review.
Trends Cardiovasc Med
July 2024
Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, F-35000 Rennes, France. Electronic address:
Quinidine, the first antiarrhythmic drug, was widely used during the 20th century. Multiple studies have been conducted to provide insights into the pharmacokinetics and pleiotropic effects of Class Ia antiarrhythmic drugs. However, safety concerns and the emergence of new drugs led to a decline in their use during the 1990s.
View Article and Find Full Text PDFAdvances and Challenges in the Management of Brugada Syndrome: A Comprehensive Review.
Cureus
June 2024
Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA.
Article Synopsis
- Brugada syndrome (BrS) is an inherited heart condition that leads to abnormal heart rhythms and an increased risk of sudden cardiac death, primarily caused by mutations in the SCN5A gene.
- Diagnosis can be tricky due to its hidden ECG signs and symptoms that resemble other heart disorders, mostly affecting young, healthy males.
- Treatment mainly involves managing symptoms and preventing sudden death, primarily through implantable cardioverter-defibrillators (ICDs), with recent advancements in catheter ablation and specific medications like quinidine showing promise despite challenges in long-term management and availability.
Brugada syndrome: identification of subjects at risk and therapy.
Eur Heart J Suppl
April 2024
Division of Cardiology, Policlinico Casilino, Rome.
Brugada syndrome mainly affects young subjects with structurally normal heart and can cause x syncope or sudden death due to ventricular arrhythmias, even as the first manifestation, in approximately 5-10% of cases. To date, two questions remain open: how to recognize subjects who will experience arrhythmic events and how to treat them. The guidelines suggest treating subjects with a previous history of cardiac arrest or arrhythmogenic syncope, while they are unconclusive about the management of asymptomatic patients, who represent ∼90% of Brugada patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!